Not a good buy right now: price is in a clear downtrend (bearish MAs + weakening MACD), and there is no proprietary buy signal to justify stepping in aggressively.
Options flow is mixed but leans defensive near-term (put volume > call volume today), which doesn’t support an impatient “buy now” approach.
With no fresh news catalysts and worsening losses in the latest reported quarter (2025/Q3), risk/reward favors staying out (or reducing) until momentum improves.
Positioning (Open Interest): Put/Call OI ratio = 0.1 → call open interest (68,989) vastly outweighs put OI (7,132), suggesting longer-dated bullish positioning/speculation.
Flow (Today’s Volume): Put/Call volume ratio = 2.03 (puts 211 vs calls 104) → today’s trading is more bearish/hedging-biased.
Activity spike: Today’s volume is ~23.61x the 30-day average → unusual attention, often seen around repositioning or risk hedges.
Volatility: 30D IV 102.78 vs HV 77.11 → options are pricing large moves; IV has cooled vs 5D avg (128.93) and 10D avg (165.67), suggesting prior fear is easing but still elevated.
Takeaway: Longer-term positioning looks optimistic (call-heavy OI), but near-term tape is defensive (put-heavy volume), which is not ideal for an immediate buy.
Technical Summary
Sell
9
Buy
3
Positive Catalysts
implying perceived upside if execution improves.
Neutral/Negative Catalysts
Strongly bearish technical structure (bearish moving-average stack + worsening MACD) increases odds that support breaks rather than holds.
Options market shows near-term caution: put volume dominating today despite call-heavy open interest.
No news in the recent week → no fresh catalyst to reverse momentum immediately.
Financing/dilution overhang highlighted by analyst model updates and prior target cuts tied to new shares.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $753K (flat YoY at 0.00%) → no meaningful top-line acceleration yet.
Profitability: Net income -$17.51M (down 55.33% YoY) and EPS -$0.11 (down 66.67% YoY) → losses widened materially.
Gross margin: 65.47% (flat YoY) → margin profile is solid on reported revenue, but scale remains the issue.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent analyst actions (Benchmark):
2026-01-21: Price target cut to $10 from $11; Buy maintained (adjusted for financing activity).
2025-11-13: Price target cut to $11 from $14 post-Q3; Buy maintained; cited new shares as a driver of the cut while noting customer/account progress.
Wall Street pros: Maintained Buy rating and cites commercial/account traction for Symvess; targets imply large upside if execution and adoption continue.
Wall Street cons: Repeated price target reductions tied to dilution/financing and the financial profile (widening losses, limited revenue scale) undermine near-term conviction.
Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.88 USD with a low forecast of 3 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.88 USD with a low forecast of 3 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.886
Low
3
Averages
5.88
High
11
Current: 0.886
Low
3
Averages
5.88
High
11
Benchmark
Buy
maintain
$11 -> $10
AI Analysis
2026-01-21
Reason
Benchmark
Price Target
$11 -> $10
AI Analysis
2026-01-21
maintain
Buy
Reason
Benchmark lowered the firm's price target on Humacyte to $10 from $11 and keeps a Buy rating on the shares after updating the firm's model for some recent financing activity, noting that its new price target is based on a sum-of-the-parts analysis.
Benchmark
Bruce Jackson
Buy
downgrade
$14 -> $11
2025-11-13
Reason
Benchmark
Bruce Jackson
Price Target
$14 -> $11
2025-11-13
downgrade
Buy
Reason
Benchmark analyst Bruce Jackson lowered the firm's price target on Humacyte to $11 from $14 and keeps a Buy rating on the shares post the Q3 report. The firm says the Symvess Acellular Tissue Engineered Vessel launch continued to gain new accounts during the quarter. It cites Humacyte's new shares for the target drop but believes the company's customer base continues to build.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HUMA
